Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Synthesis and in vitro evaluation of novel 2-oxo-1,2-dihydroquinoline CB2 receptor inverse agonists.

Raitio KH, Savinainen JR, Nevalainen T, Järvinen T, Vepsäläinen J.

Chem Biol Drug Des. 2006 Dec;68(6):334-40.

PMID:
17177896
2.

Synthesis and SAR studies of 2-oxoquinoline derivatives as CB2 receptor inverse agonists.

Raitio KH, Savinainen JR, Vepsäläinen J, Laitinen JT, Poso A, Järvinen T, Nevalainen T.

J Med Chem. 2006 Mar 23;49(6):2022-7.

PMID:
16539390
3.

Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.

Stern E, Muccioli GG, Millet R, Goossens JF, Farce A, Chavatte P, Poupaert JH, Lambert DM, Depreux P, Hénichart JP.

J Med Chem. 2006 Jan 12;49(1):70-9.

PMID:
16392793
4.

Synthesis and pharmacological evaluation of coumarin derivatives as cannabinoid receptor antagonists and inverse agonists.

Behrenswerth A, Volz N, Toräng J, Hinz S, Bräse S, Müller CE.

Bioorg Med Chem. 2009 Apr 1;17(7):2842-51. doi: 10.1016/j.bmc.2009.02.027. Epub 2009 Feb 21.

PMID:
19278853
5.

Suppression of food intake and food-reinforced behavior produced by the novel CB1 receptor antagonist/inverse agonist AM 1387.

McLaughlin PJ, Qian L, Wood JT, Wisniecki A, Winston KM, Swezey LA, Ishiwari K, Betz AJ, Pandarinathan L, Xu W, Makriyannis A, Salamone JD.

Pharmacol Biochem Behav. 2006 Mar;83(3):396-402. Epub 2006 Mar 6.

PMID:
16616951
6.

1-Benzhydryl-3-phenylurea and 1-benzhydryl-3-phenylthiourea derivatives: new templates among the CB1 cannabinoid receptor inverse agonists.

Muccioli GG, Wouters J, Scriba GK, Poppitz W, Poupaert JH, Lambert DM.

J Med Chem. 2005 Nov 17;48(23):7486-90.

PMID:
16279809
7.

Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.

Stern E, Muccioli GG, Bosier B, Hamtiaux L, Millet R, Poupaert JH, Hénichart JP, Depreux P, Goossens JF, Lambert DM.

J Med Chem. 2007 Nov 1;50(22):5471-84. Epub 2007 Oct 4.

PMID:
17915849
8.

Cannabinoid receptor antagonists: pharmacological opportunities, clinical experience, and translational prognosis.

Janero DR, Makriyannis A.

Expert Opin Emerg Drugs. 2009 Mar;14(1):43-65. doi: 10.1517/14728210902736568 . Review.

PMID:
19249987
9.
10.

1,2,3-Triazole derivatives as new cannabinoid CB1 receptor antagonists.

Hou DR, Alam S, Kuan TC, Ramanathan M, Lin TP, Hung MS.

Bioorg Med Chem Lett. 2009 Feb 1;19(3):1022-5. doi: 10.1016/j.bmcl.2008.11.029. Epub 2008 Nov 14.

PMID:
19095444
11.

Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies.

Lavey BJ, Kozlowski JA, Hipkin RW, Gonsiorek W, Lundell DJ, Piwinski JJ, Narula S, Lunn CA.

Bioorg Med Chem Lett. 2005 Feb 1;15(3):783-6.

PMID:
15664857
12.

Characterization of a novel and selective cannabinoid CB1 receptor inverse agonist, Imidazole 24b, in rodents.

Shearman LP, Stribling DS, Camacho RE, Rosko KM, Wang J, Tong S, Feng Y, Marsh DJ, Yu H, Guan X, Spann SK, Macneil DJ, Fong TM, Metzger JM, Goulet MT, Hagmann WK, Plummer CW, Finke PE, Mills SG, Shah SK, Truong Q, Van der Ploeg LH, Macintyre DE, Strack AM.

Eur J Pharmacol. 2008 Jan 28;579(1-3):215-24. Epub 2007 Oct 25.

PMID:
18021763
13.

Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.

Brogi S, Corelli F, Di Marzo V, Ligresti A, Mugnaini C, Pasquini S, Tafi A.

Eur J Med Chem. 2011 Feb;46(2):547-55. doi: 10.1016/j.ejmech.2010.11.034. Epub 2010 Nov 27.

PMID:
21183257
14.

Cannabilactones: a novel class of CB2 selective agonists with peripheral analgesic activity.

Khanolkar AD, Lu D, Ibrahim M, Duclos RI Jr, Thakur GA, Malan TP Jr, Porreca F, Veerappan V, Tian X, George C, Parrish DA, Papahatjis DP, Makriyannis A.

J Med Chem. 2007 Dec 27;50(26):6493-500. Epub 2007 Nov 27.

PMID:
18038967
15.

6-Methoxy-N-alkyl isatin acylhydrazone derivatives as a novel series of potent selective cannabinoid receptor 2 inverse agonists: design, synthesis, and binding mode prediction.

Diaz P, Phatak SS, Xu J, Astruc-Diaz F, Cavasotto CN, Naguib M.

J Med Chem. 2009 Jan 22;52(2):433-44. doi: 10.1021/jm801353p.

PMID:
19115816
16.

5-Sulfonyl-benzimidazoles as selective CB2 agonists.

Verbist BM, De Cleyn MA, Surkyn M, Fraiponts E, Aerssens J, Nijsen MJ, Gijsen HJ.

Bioorg Med Chem Lett. 2008 Apr 15;18(8):2574-9. doi: 10.1016/j.bmcl.2008.03.048. Epub 2008 Mar 20.

PMID:
18394887
17.

Design, synthesis and biological evaluation of piperazine analogues as CB1 cannabinoid receptor ligands.

Song KS, Lee SH, Chun HJ, Kim JY, Jung ME, Ahn K, Kim SU, Kim J, Lee J.

Bioorg Med Chem. 2008 Apr 1;16(7):4035-51. doi: 10.1016/j.bmc.2008.01.023. Epub 2008 Jan 19.

PMID:
18243711
19.

Antinociceptive effects of the non-selective cannabinoid receptor agonist CP 55,940 are absent in CB1(-/-) and not CB2(-/-) mice in models of acute and persistent pain.

Sain NM, Liang A, Kane SA, Urban MO.

Neuropharmacology. 2009 Sep;57(3):235-41. doi: 10.1016/j.neuropharm.2009.06.004. Epub 2009 Jun 16.

PMID:
19538975
20.

4-Oxo-1,4-dihydropyridines as selective CB2 cannabinoid receptor ligands: structural insights into the design of a novel inverse agonist series.

El Bakali J, Muccioli GG, Renault N, Pradal D, Body-Malapel M, Djouina M, Hamtiaux L, Andrzejak V, Desreumaux P, Chavatte P, Lambert DM, Millet R.

J Med Chem. 2010 Nov 25;53(22):7918-31. doi: 10.1021/jm100286k. Epub 2010 Oct 27.

PMID:
20979417

Supplemental Content

Support Center